Valuation: Indivior Pharmaceuticals, Inc.

Market Cap 4.93B 4.32B 4.01B 3.69B 6.95B 476B 7.05B 47.79B 18.7B 233B 18.51B 18.11B 804B P/E 2026 *
12.7x
P/E 2027 * 11.2x
Enterprise Value 4.99B 4.37B 4.06B 3.73B 7.02B 481B 7.13B 48.32B 18.91B 235B 18.72B 18.31B 813B EV / Sales 2026 *
3.96x
EV / Sales 2027 * 3.45x
Free-Float
97.23%
Yield 2026 *
-
Yield 2027 * -
1 week+5.27%
1 month+20.78%
3 months+60.36%
6 months+29.91%
Current year+20.90%
1 week 1,160
Extreme 1160
1,264
1 month 975.5
Extreme 975.5
1,264
3 years 554.83
Extreme 554.83
2,020
5 years 335
Extreme 335
2,020
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%+5.27%+49.52%-20.18% 4.93B
-1.05%+0.91%+52.59%+151.71% 1,048B
+2.00%+0.70%+55.53%+50.20% 603B
-1.09%+3.48%+37.03%+76.22% 452B
-0.42%+1.65%+30.05%+21.05% 327B
-0.16%+2.39%+36.91%+37.33% 283B
+1.68%+2.73%+24.14%+17.94% 259B
-1.40%-0.06%-22.24%-42.39% 219B
-0.05%+3.04%+23.72%+55.89% 198B
+0.05%+0.23%+20.37%+61.63% 162B
Average +0.01%+1.74%+30.76%+40.94% 394.63B
Weighted average by Cap. -0.01%+1.69%+38.04%+72.41%

Financials

2026 *2027 *
Net sales 1.26B 1.1B 1.02B 942M 1.77B 122B 1.8B 12.21B 4.78B 59.5B 4.73B 4.63B 206B 1.31B 1.15B 1.07B 981M 1.85B 127B 1.88B 12.72B 4.98B 61.97B 4.93B 4.82B 214B
Net income 414M 363M 337M 310M 584M 39.99B 592M 4.02B 1.57B 19.57B 1.56B 1.52B 67.6B 473M 414M 385M 353M 666M 45.63B 676M 4.58B 1.79B 22.33B 1.78B 1.74B 77.13B
Net Debt 54.5M 47.75M 44.33M 40.74M 76.76M 5.26B 77.89M 528M 207M 2.57B 205M 200M 8.89B -403M -353M -328M -302M -568M -38.93B -577M -3.91B -1.53B -19.05B -1.51B -1.48B -65.8B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
40.45USD
Average target price
50.83USD
Spread / Average Target
+25.67%

Quarterly revenue - Rate of surprise